Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anaphore's Bowdish made president and CSO at Permeon

This article was originally published in Scrip

Executive Summary

Permeon Biologics, a company developing intracellular biologics that target a broad spectrum of previously undruggable targets, has appointed Dr Katherine Bowdish president and chief scientific officer. Dr Bowdish also joins the board of directors. She previously co-founded drug development company Anaphore, and served as the firm's president and CEO. Dr Bowdish resigned as Anaphore's CEO in June 2011 and has since served the company as a consultant (scripintelligence.com, 21 June 2011).

Related Companies

UsernamePublicRestriction

Register

SC016414

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel